Written by Healing Sky Editorial Team. Clinically reviewed by Cosette Pulido M.D.
Opioid use disorder treatment has changed considerably with the arrival of once‑monthly injectable buprenorphine. Sublocade delivers a full month of steady medication in a single in‑clinic injection, removing the daily dosing routine that trips up many people on sublingual buprenorphine. For adults with moderate to severe OUD who want reliable craving control without managing pills or films every morning, it represents a practical shift in how maintenance treatment can work. It is FDA‑approved as part of a treatment plan that includes counseling and recovery supports, and it falls under the broader category of medications for opioid use disorder (MOUD, previously called medication‑assisted treatment or MAT).
Daily sublingual buprenorphine (for example, Suboxone) can be highly effective. Yet for many people, life gets in the way. Lost films or pills, chaotic mornings, privacy concerns, travel, and the stress of daily decision‑making can all erode adherence. A long‑acting injectable buprenorphine maintenance plan addresses several of these barriers at once: medication levels stay consistent without daily pills or films, the chance of missed doses or diversion drops, and patients gain more time and mental space to engage in therapy, work, and family life.
Beyond convenience, taking medication for opioid use disorder reduces the risk of death, which is one reason MOUD is considered a gold‑standard, lifesaving treatment.
Buprenorphine is a partial opioid agonist. It attaches to the same receptors that opioids use but activates them only partially. This "ceiling effect" steadies the system, quiets withdrawal, and reduces cravings without producing the intense highs of full‑agonist opioids. Sublocade packages buprenorphine in a small, biodegradable depot injected under the skin, which slowly releases medication over a full month, keeping blood levels steady and minimizing the day‑to‑day peaks and valleys that can occur with sublingual dosing. Sublocade is prepared and administered by a healthcare professional and is available only through a restricted program (the SUBLOCADE REMS) that requires certified healthcare settings and pharmacies for safe handling and in‑clinic administration.
Sublocade is intended for adults with OUD who want structure and steadiness in their treatment. It is especially helpful for people who want a discreet, once‑monthly treatment that reduces daily medication tasks, who have struggled with remembering or securing daily sublingual doses, or who prefer to lower the risks of diversion, tampering, or lost medication.
Sublocade is not appropriate for people who are opioid‑naïve or for those with certain medical conditions discussed below. The decision is based on health history, current substance use, goals, and personal preferences.
The current Sublocade label allows most appropriate patients to start treatment on Day 1. For patients not already on buprenorphine, a small test dose of a transmucosal buprenorphine product (for example, 4 mg) is given first to confirm tolerability. After one hour of observation, the first Sublocade injection can be administered the same day. Patients already stable on daily buprenorphine can often transition directly to Sublocade at the first visit.
The typical dosing plan:
This accelerated start and flexible second‑dose timing help move quickly from the fragility of early withdrawal to stable maintenance, an advantage in today's fentanyl‑heavy landscape.
The visit is straightforward and usually takes under 30 minutes. Sublocade is injected just under the skin at one of four approved sites: the abdomen, buttock, thigh, or the back of the upper arm. Locations are rotated to minimize irritation, and the site is chosen with patient comfort and discretion in mind. Most patients feel pressure and a brief burning sensation as the medication is delivered, which resolves quickly.
Afterward, a small, firm lump under the skin at the injection site is normal. That is the depot steadily releasing buprenorphine through the month; it gradually softens and shrinks. The area should not be rubbed or massaged, and tight belts or waistbands that press on it should be avoided.
Seek care promptly if any of the following occur at the injection site:
A few comfort measures many patients find helpful:
The most common feedback after the first couple of doses is a sense of "mental quiet." Without daily medication decisions and with continuous receptor coverage, cravings and withdrawal fade into the background. People often report improved sleep, steadier mood, and more bandwidth for therapy, work, and family routines. There is no daily dosing routine because medication is always on board, the risk of diversion or lost medication drops, and some patients find it reduces stigma by eliminating visible medication supplies at home.
When cravings or breakthrough withdrawal occur, especially early on, the maintenance dose can be increased to 300 mg when the expected benefits outweigh the risks.
Like any opioid medication, buprenorphine can cause side effects. With Sublocade, the most common are constipation, nausea, headache, fatigue, and injection‑site discomfort or itch. These are often mild and manageable. Rarely, more serious injection‑site reactions can occur and may require medical care.
Several safety points require attention. Respiratory depression can occur, especially if Sublocade is combined with alcohol, benzodiazepines, gabapentinoids, or other sedatives; patients should receive counseling on safer use, and naloxone should be kept at home and with loved ones. Liver health matters: liver enzymes are checked before and during treatment, and starting Sublocade is not recommended for people with moderate to severe hepatic impairment. If liver issues develop during treatment, monitoring for toxicity or overdose symptoms is warranted. Patients should use caution when driving or operating machinery until they know their personal response, particularly after the first dose or a dose change, as some people experience drowsiness or slowed reaction time.
Regarding pregnancy and breastfeeding: buprenorphine is an accepted standard of care in pregnancy. Newborns may have neonatal opioid withdrawal syndrome (NOWS), which is treatable. SUBLOCADE data in pregnancy are limited, so SUBLOCADE should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Anyone who becomes pregnant or is planning pregnancy should discuss benefits and risks with their care team and coordinate with their obstetric provider.
Because Sublocade forms a depot, buprenorphine can be detectable in the body for several months after the last injection. If treatment stops, follow‑up should continue for several months and any withdrawal that emerges should be treated. For surgeries or sudden injuries, non‑opioid pain strategies are typically prioritized; if opioids are unavoidable, higher‑than‑usual doses of a full agonist may be required, and close monitoring is necessary.
Patients have options, and the best one is the one that can be maintained comfortably and safely. The three main buprenorphine formulations differ in practical ways:
The choice involves dose flexibility, clinic logistics, insurance coverage, prior authorization, and personal preference.
Most people on Sublocade continue with their usual activities: work, school, parenting, exercise, and travel. A few practical considerations are worth planning for. Travel requires coordinating appointments ahead of time; there is a small window to give maintenance doses early or slightly late, but the schedule should be discussed in advance to avoid a missed injection. Until a patient knows their personal response, especially after the first one or two injections, high‑risk tasks such as driving should be approached with caution. Medication works best alongside therapy, mutual‑support options, family involvement (if chosen), and concrete personal goals.
If a switch back to daily buprenorphine or another MOUD is ever needed, a safe transition plan can be mapped out.
Monthly visits are more than an injection. The appointment covers symptoms, cravings, sleep, mood, use patterns, urine toxicology (as appropriate), and recovery goals. The injection site is examined and locations are rotated to minimize irritation. Breakthrough cravings or exposure to high‑potency opioids like fentanyl may prompt dose adjustments or added supports. Safety is reassessed at each visit, including medication interactions, alcohol use, and sedation risk. Naloxone is refilled as needed, and coordination with a therapist or case manager occurs with patient consent.
Will I feel "high"? Most patients do not. Sublocade is designed to quiet withdrawal and cravings, not produce euphoria.
What if I miss a dose? Contact the clinic as soon as possible. The next dose can be administered promptly and the schedule reset. Short delays of up to about two weeks generally do not change clinical effect, but a steady rhythm is best.
Can I start Sublocade if I used yesterday? Withdrawal level will be assessed. If objective signs are present, buprenorphine tolerability can be confirmed with a small test dose, and Sublocade can be given on Day 1 with observation to ensure stabilization rather than worsening.
Will there be a bump under my skin? Yes, a small lump is expected and shrinks over weeks. It should not be pressed, rubbed, or manipulated, and clothing that rubs on the site should be avoided.
Can I take anxiety medications? Combining benzodiazepines, alcohol, or other sedatives with buprenorphine can slow breathing. When these medications are necessary, the lowest effective doses should be used, clear safety guidance should be provided, and naloxone should be available.
Sublocade is not recommended for people with moderate to severe liver impairment at baseline, and it is not appropriate for those who are opioid‑naïve. A history of serious allergic reactions to buprenorphine or components of the formulation rules it out. It is also not a workable option when a patient cannot safely attend monthly in‑clinic injections or has untreated medical issues that make the risks outweigh the benefits.
Most health plans, including Medicaid and many commercial insurers, cover long‑acting buprenorphine injections, though prior authorization is common. Sublocade is distributed through a restricted program and administered only by certified healthcare settings. At Healing Sky, the care team coordinates benefits, specialty pharmacy delivery, storage, and scheduling so medication is on hand at each appointment. For patients who are uninsured or underinsured, assistance options and alternatives can be discussed to ensure access to effective MOUD.
Medication is one pillar of treatment. Healing Sky pairs Sublocade maintenance with collaborative goal‑setting, evidence‑based therapy and skills coaching, harm‑reduction training for patients and loved ones (including naloxone), and practical help with sleep, mood, work and school coordination, and transitions such as switching from daily buprenorphine or planning a taper.
If you are considering long‑acting injectable buprenorphine maintenance, a brief consultation can clarify whether Sublocade, another MOUD, or a stepped approach is the best fit. At Healing Sky, patients meet with a board‑certified psychiatrist who will explain options in plain language and personalize the plan. One monthly visit can change the rhythm of daily life, creating room to focus on what matters most.
Medically reviewed by Cosette Pulido, M.D.
Read More
(NA)
Read More
(NA)
Read More
(NA)
Sign up now to get unrestricted access to Healing Sky's online mental health directory, resources, and more!
Sign up now
